- Home
- CELH vs BMRN Comparison
CELH vs BMRN Comparison
Compare CELH & BMRN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CELH | BMRN |
|---|---|---|
| Founded | 2004 | 1996 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Beverages (Production/Distribution) | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 10.1B | 10.5B |
| IPO Year | N/A | 1999 |
Fundamental Metrics
Financial Performance| Metric | CELH | BMRN |
|---|---|---|
| Price | $41.97 | $53.19 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 18 | 19 |
| Target Price | $62.39 | ★ $88.42 |
| AVG Volume (30 Days) | ★ 8.1M | 3.0M |
| Earning Date | 11-06-2025 | 10-27-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 59.53 |
| EPS | 0.13 | ★ 2.68 |
| Revenue | $2,125,838,000.00 | ★ $3,094,001,000.00 |
| Revenue This Year | $83.38 | $13.39 |
| Revenue Next Year | $32.58 | $7.57 |
| P/E Ratio | $348.06 | ★ $19.92 |
| Revenue Growth | ★ 55.07 | 12.39 |
| 52 Week Low | $21.10 | $50.76 |
| 52 Week High | $66.74 | $73.51 |
Technical Indicators
Market Signals| Indicator | CELH | BMRN |
|---|---|---|
| Relative Strength Index (RSI) | 40.10 | 46.19 |
| Support Level | $40.65 | $53.03 |
| Resistance Level | $43.28 | $54.66 |
| Average True Range (ATR) | 1.95 | 1.45 |
| MACD | 0.80 | -0.11 |
| Stochastic Oscillator | 78.03 | 31.61 |
Price Performance
Historical ComparisonAbout CELH Celsius Holdings Inc.
Celsius Holdings plays in the energy drink subsegment of the global nonalcoholic beverage market, with 95% of revenue concentrated in North America. The firm now owns three energy drink brands: Celsius, Alani Nu, and Rockstar Energy. It dedicates its efforts to product innovation and marketing while outsourcing manufacturing and packaging to third-party co-packers and distribution to PepsiCo. The firm issued convertible preferred shares following PepsiCo's investments in 2022 and 2025, giving the latter an 11% stake in Celsius.
About BMRN BioMarin Pharmaceutical Inc.
BioMarin is a global biotechnology company focused on developing and commercializing therapies for rare genetic diseases. BioMarin specializes in enzyme replacement therapies, gene therapies, and other advanced treatments designed to address complex genetic disorders. The company has eight approved therapies for conditions including achondroplasia, phenylketonuria, hemophilia, and mucopolysaccharidosis. BioMarin has an expanding, yet relatively early-stage, pipeline of treatments in development across skeletal conditions and enzyme therapies.